The FDA approved an additional indication of darolutamide (Nubeqa, Bayer) in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). Darolutamide now has indications in both mHSPC and nonmetastatic castration-resistant prostate cancer (nmCRPC).
“Darolutamide plus ADT and docetaxel has shown significant benefit in overall survival and a favorable safety profile for patients with metastatic hormone-sensitive prostate cancer,” said Matthew